The impact of COVID-19 on opioid treatment programs in the United States

BACKGROUND: The COVID-19 pandemic had the potential to severely disrupt the delivery of methadone and buprenorphine, as social distancing and other public health regulations made in-person services difficult to maintain. Federal and state regulators changed requirements regarding the dispensing of m...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldsamt, Lloyd A., Rosenblum, Andrew, Appel, Philip, Paris, Philip, Nazia, Nasreen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461004/
https://www.ncbi.nlm.nih.gov/pubmed/34600258
http://dx.doi.org/10.1016/j.drugalcdep.2021.109049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461004/
https://www.ncbi.nlm.nih.gov/pubmed/34600258
http://dx.doi.org/10.1016/j.drugalcdep.2021.109049

Ejemplares similares